Why the study?
Does fenflumizole inhibit platelet aggregation and prevent arachidonate-induced sudden death in rabbits compared to aspirin or ticlopidine?
Does fenflumizole inhibit platelet aggregation and prevent arachidonate-induced sudden death in rabbits compared to aspirin or ticlopidine?
Answers are grounded in this paper and cite their sources.
Fenflumizole is a highly potent antiplatelet agent in rabbit models, significantly more effective than aspirin and ticlopidine at inhibiting aggregation and preventing arachidonate-induced death.
The antiplatelet effect of fenflumizole, compared with aspirin or ticlopidine, was examined in in vitro, ex vivo and in vivo situations of the rabbit. Unlike ticlopidine, fenflumizole and aspirin effectively inhibited in vitro the platelet aggregation elicited by arachidonate and collagen. The activity of fenflumizole was 350 times more potent than that of aspirin. Fenflumizole (0.3-3 mg/kg) given p.o. was 4.2 and 8.1 times more potent than aspirin in inhibiting arachidonate- and collagen-induced platelet aggregations, respectively. Ticlopidine (300 mg/kg, p.o.) resulted in only weak effects on the aggregations. Fenflumizole (3 mg/kg) as well as aspirin (10 mg/kg) given p.o., unlike ticlopidine (300 mg/kg), effectively prevented the arachidonate-induced sudden death.
No takes yet. Share an insight, caveat, or question.
Aono et al. (1986) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: